Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 –

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co

Lyon (France), May 28, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co

Lyon (France), le 28 mai 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée

Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while managemen

Valneva SE (VALN) Q1 2026 Earnings Call Transcript

Valneva (NASDAQ:VALN) lowers FY2026 sales outlook from $180.443 million-$197.906 million to $169.795

Valneva (NASDAQ:VALN) reported quarterly losses of $(0.42) per share which missed the analyst consen

Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o

Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon

Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co

US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting l

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy s

Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficac

Dow Jones rises over 800 points on Monday as U.S. stocks trade higher. NASDAQ and S&P 500 also s

Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 r

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease

Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against seri

Dow futures up 200 points, ClearPoint Neuro (CLPT) stock falls after wider-than-expected quarterly l

Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $180.443 million-$197.906 million to $180.44

Valneva (NASDAQ:VALN) reported quarterly losses of $(0.68) per share which missed the analyst consen

U.S. stock futures higher, Dow up 100 points. Zepp Health shares fell 11% after reporting losses. Ot

ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,

Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) ga

Total Revenues of €174.7 million in line with guidance, including €157.9 million in product salesStr

Valneva SE  (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that following a

Valneva withdraws U.S. applications for its chikungunya vaccine Ixchiq after the FDA suspended the l

Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opp